Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it ...

Sarepta Therapeutics sells 9.3M Arrowhead shares for $174M and fulfills a $100M milestone payment. Read more here.

Sarepta Therapeutics is selling off Arrowhead Pharmaceuticals’ shares to stretch its cash runway, while also inking a share ...

Arrowhead PharmaceuticalsARWR stock tumbled Thursday after Sarepta TherapeuticsSRPT liquefied its entire stake in the smaller biotech company.The beleaguered biotech giant sold more than 9.2 million ...

Sarepta sells $174M in Arrowhead shares to fund a $100M milestone payment as part of its RNAi drug collaboration.

Sarepta Therapeutics Inc.’s shares soared after the US biotech reported revenue that beat estimates, which analysts ...

The milestone payment is partially funded through Sarepta’s Arrowhead stock sale as both companies push forward with ...

After a second Elevidys patient death from acute liver failure, Sarepta in July launched a major restructuring that involves ...

In the wake of multiple patient deaths from liver injuries related to Sarepta Therapeutics’ AAV gene therapy platform, some ...

Sarepta Therapeutics said Friday that the deaths of two patients taking its marketed gene therapy Elevidys® (delandistrogene ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

We expect Sarepta Therapeutics SRPT to report second-quarter 2025 earnings on Aug. 6, after market close. The company’s ...